SPR1020 for advanced solid tumors with DNA repair defects
Part of Cancer clinical trials.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with an advanced solid tumor that has spread or cannot be removed by surgery.
- Your tumor must have a BRCA or other HRD gene mutation (breast, ovarian, prostate, or pancreatic cancers are priorities).
- You must have tried at least one standard treatment that no longer works, or you cannot tolerate standard therapy.
- You must be in fairly good health (ECOG 0 or 1), with adequate organ function (blood, liver, kidneys).
- You must provide tumor tissue or blood sample for genetic testing within 12 months before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug (EIK1004) designed to block a protein called PARP1, which helps repair DNA. It is for people with advanced solid tumors, especially those with BRCA or other DNA repair gene mutations. The goal is to see if it can shrink tumors or slow their growth.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new drug called ASN-3186 for people with advanced solid tumors that have not responded to other treatments. It may help those whose tumors have specific genetic changes, like BRCA mutations.
This trial tests a new pill called DAT-2645 for people with advanced solid tumors that have a specific DNA repair problem (like a BRCA gene change). It aims to see if the drug is safe and effective when standard treatments have stopped working.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
Hear when a new PARP Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.